Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Early-onset colorectal cancer (under 50), drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The cause of the rise is unknown; no exposure has been proven.
Diagnostic delay in young adults with rectal bleeding remains long.
Whether screening should start at 45, 40 or by individual risk is unsettled outside the United States.
Background: Faecal immunochemical test (FIT). Also on OnCo: Symptoms and red flags · Early detection roadmap.
Fertility, sexual function and financial toxicity are poorly measured in trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
DFS HR 0.
A milestone in how this cancer is treated.
Sensitivity 83.
10-year colorectal cancer risk 0.
A milestone in how this cancer is treated.